CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
Adoptive transfer of chimeric antigen receptor (CAR)-modified T cells has resulted in unprecedented rates of long-lasting complete responses in patients with leukemia and lymphoma. However, despite the impressive results in patients with hematologic malignancies, CAR-T cells have showed limited effe...
Main Authors: | Sonia Guedan, Ramon Alemany |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.02460/full |
Similar Items
-
CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
by: Alba Rodriguez-Garcia, et al.
Published: (2020-06-01) -
Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors
by: Francesco Boccalatte, et al.
Published: (2022-10-01) -
CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar
by: Kun Chen, et al.
Published: (2023-10-01) -
Strategies for Dodging the Obstacles in CAR T Cell Therapy
by: Pooria Safarzadeh Kozani, et al.
Published: (2021-04-01) -
CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors
by: Vicky Mengfei Qin, et al.
Published: (2022-01-01)